Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
The Bent's new season starts with a bang, thanks to their production of this gay adaptation of La Ronde by Arthur Schnitzler.
The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...
To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to ...
As the nation's AIDS walk marks its 40th year in Los Angeles, organizers say medical advances have taken lowered visibility ...
As healthcare costs soar, the Congressional Budget Office (CBO) has recently shed light on a hot political issue: the ...
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...
Recommended Reading Gilead agrees to license new HIV drug in low-income countries GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it will make ...
Justice secretary Shabana Mahmood is facing pressure from the public to link early releases from prison to drug testing, a new poll suggests. Polling of 2,001 adults conducted by Opinion Matters ...
Gilead Sciences has announced that cheaper versions of its “gamechanger” HIV prevention drug, lenacapavir, will be made available in 120 low and middle income countries. Lenacapavir is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback